BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: This type of BIM protein promotes drug resistance in NSCLC (non-small cell lung cancer) and CML (chronic myeloid leukemia) against tyrosine kinase inhibitors such as gefitinib and imatinib[67].